Sign In
Buy APRE
$0.762
-0.0022 (-0.288%)
At Close: Jun 03, 2026
APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Skyrocketing Today
12:07pm, Wednesday, 16'th Jun 2021
Aprea Therapeutics (APRE) stock is seeing major gains on Wednesday after revealing results from a recent Phase 1/2 trial. The post APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics S
APRE Stock Price Increases Over 40%: Why It Happened
10:30am, Wednesday, 16'th Jun 2021
The stock price of Aprea Therapeutics, Inc. (NASDAQ: APRE) increased by over 40% during intraday trading this morning. This is why it happened.
Why Aprea Therapeutics Shares Are Surging Today
09:06am, Wednesday, 16'th Jun 2021
Aprea Therapeutics Inc (NASDAQ:APRE) shares are trading higher by 46% at $7.07 after the company announced the Phase 1/2 trial of eprenetapopt with venetoclax and azacitidine in TP53 mutant AML met th
Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit
06:00am, Friday, 21'st May 2021
BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant
Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
06:00am, Tuesday, 18'th May 2021
BOSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant
Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
09:15am, Friday, 16'th Apr 2021
BOSTON, April 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
11:15am, Thursday, 08'th Apr 2021
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the
Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
04:15pm, Tuesday, 16'th Mar 2021
BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
12:53pm, Tuesday, 23'rd Feb 2021
Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Aprea Therapeutics, Inc. (APRE) a New Buy Stock
12:47pm, Friday, 22'nd Jan 2021
Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
08:00am, Friday, 08'th Jan 2021
BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the m
APRE Stock Price: $6 Target By Morgan Stanley
12:30pm, Tuesday, 29'th Dec 2020
Shares of Aprea Therapeutics Inc (NASDAQ: APRE) have received a target price decrease from $34 to $6 from Morgan Stanley. These are the details.
Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal
11:17am, Tuesday, 29'th Dec 2020
Aprea (APRE) down as late-stage study on lead candidate, eprenetapopt, combined with azacitidine (AZA) versus AZA alone in TP53 mutant myelodysplastic syndromes (MDS) fails.
Is Aprea Therapeutics Doomed?
12:14pm, Monday, 28'th Dec 2020
Aprea Therapeutics Inc. (NASDAQ: APRE) stock was absolutely crushed to start out the week after the company announced results from its late-stage trial evaluating the safety and efficacy of its treatm
BOSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the m
